DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for non-Hodgkins lymphoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNon-Hodgkins lymphoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedPaclitaxelApproved drug
Structures already discussed alongside non-hodgkins lymphoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Refined structure of alpha-beta tubulin from zinc-induced sheets stabilized — Paclitaxel has a real, experimentally solved structure in complex with this target (PDB 1JFF, 3.5 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ta1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1JFF · 3.5 Å · ligand Paclitaxel (TA1). Experimental structure, not a prediction.
What the evidence adds up to
A 1999 study of paclitaxel in 38 patients with relapsed or refractory aggressive non-Hodgkin lymphoma reported a partial remission rate of 8.6% (3 of 35 evaluable patients), with responses lasting a median of 2 months. Stable disease was seen in 31.4% (11 patients), median duration 3 months. Median survival from start of treatment was 5.4 months; estimated 1-year and 2-year survival rates were 34% and 27%. The authors concluded that paclitaxel at 175 mg/m² as a 3-hour infusion produced minimal antitumour activity in this setting. Febrile neutropenia occurred in two patients, and grade III alopecia in 19.
A 2011 review of non-Hodgkin lymphoma pathogenesis summarised advances in molecular biology that have identified oncogenic pathways in lymphomagenesis, particularly in diffuse large B-cell lymphoma, the most common subtype. The review stated that this knowledge would ultimately lead to improved diagnostic and therapeutic strategies, but provided no clinical trial data.
Several abstracts concern Hodgkin lymphoma, a separate disease. A 2013 review noted that cure was possible but morbidity high with older regimens, and that trials now aim to maximise cure and minimise toxicity. A 2022 study reported that for stage I-II Hodgkin lymphoma treated with chemotherapy followed by involved-field radiation, the HD10 trial showed a 10-year progression-free survival rate of 87%. A 2018 review stated that most Hodgkin lymphoma patients are cured after first-line treatment, and that relapsed or refractory patients often achieve another remission. A 2021 review of Hodgkin lymphoma in Nigeria noted that the country bears the second highest burden of HIV globally, and that HIV-infected persons with lymphoma have a 2.5-times lower 2-year survival chance compared to HIV-uninfected persons; late stage at diagnosis contributed to worse outcomes.
No abstract in this set provides evidence for a drug that has been repurposed for non-Hodgkin lymphoma. The only drug tested, paclitaxel, showed low activity in relapsed or refractory disease. What remains missing are trials that test drugs with known mechanisms against the specific molecular subtypes now recognised in non-Hodgkin lymphoma, adequate funding for such trials, and patient stratification by genetic or viral status.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Oncology · 2011 · 230 citations
Pathogenesis of Non-Hodgkin's Lymphoma
AbstractThe understanding of the molecular pathogenesis of non-Hodgkin's lymphomas (NHL) has significantly improved in recent years. Advances in molecular biology and genetics lead to the identification and characterization of several oncogenic pathways involved in lymphomagenesis. This knowledge will ultimately lead to improved diagnostic and therapeutic strategies for patients with NHL. This review summarizes current concepts of the molecular pathogenesis of the most common NHL subtypes, with a special emphasis on diffuse large B-cell lymphoma, the most common lymphoma subtype.
Leukemia & lymphoma/Leukemia and lymphoma · 1999 · 16 citations
Combined Results of Two Phase Il Studies of Taxol (Paclitaxel) in Patients with Relapsed or Refractory Lymphomas
AbstractThis study was performed to determine the clinical activity and safety of paclitaxel in the treatment of patients with refractory or relapsing aggressive Non-Hodgkin's lymphoma (NHL). Between May 3, 1994 and February 16, 1996, 39 patients with refractory or relapsing NHL consented to be enrolled in two, multicenter, open-labelled studies to evaluate the efficacy, safety, time to progression and overall survival of paclitaxel given at a dose of 175 mg/m2 by a 3-hour IV infusion every three weeks without G-CSF use. Data from the two studies is combined. One patient, although registered, did not receive treatment. Of the remaining 38 patients, 17 men and 21 women aged 26-82 years (median 60) were given 104 courses of paclitaxel [median 2 (range 1-6)]. Seventeen patients had stage IV, 7 stage III, 8 stage II, 5 stage 1 and 1 unknown stage of disease. Histologic grades included 1 low, 33 intermediate, and 4 high. Three patients had bone marrow involvement. Median time from diagnosis to study entry was 19 months (1-160). The median number of previous chemotherapy regimens was 2 (range 1-6). Three of the 35 (8.6%) patients evaluable for response had partial remission (PR) of their disease for 1-7 months (median 2) and 11/35 (31.4%) stable disease (SD) for 1 to 19 months (median 3). All three responders and 3 of the 11 SD patients had received paclitaxel after relapsing from a CR. At analysis, nine of the 38 patients were alive. Median duration of follow up at analysis was 6 months (3 days-29 months). The estimated survival rates for all patients at 1 and 2 years are 34% and 27%, respectively (Kaplan-Meier) from the start of paclitaxel treatment. The median survival time was 5.4 months (3 days to 28+ months). Febrile neutropenia occurred in two patients. Seven (18%) patients developed a neutrophil nadir of < 0.5 x 10(9)/L and 2 (5%) patients developed a platelet nadir of < 50 x 10(9)/L. Six patients received blood transfusions. Non-hematologic toxicity was generally mild to moderate with all patients experiencing some toxicity. Twenty-seven patients experienced grade III toxicity including: alopecia (n = 19), pain (n = 9), fatigue (n = 5), nausea/vomiting (n = 3), diarrhoea (n = 2), pulmonary/shortness of breath (n = 2), anorexia (n = 1) and fluctuating levels of consciousness and somnolence (n = 1). Two patients experienced grade IV toxicity (infection, peripheral neuropathy, pain). No patient discontinued paclitaxel for a severe hypersensitivity reaction. In summary, administered as a 3-hour infusion, paclitaxel 175 mg/m2 results in mild myelotoxicity but minimal antitumor activity in patients with refractory NHL.
British Journal of Hospital Medicine · 2013 · 7 citations
Classical Hodgkin's lymphoma: past, present and future perspectives
AbstractHodgkin's lymphoma treatment is a modern medical success story. Historically, staging involved invasive laparotomies, chemotherapy was highly emetogenic, and radiotherapy extensive. Cure was possible, but morbidity high. Now trials aim to maximize cure, minimize toxicity and introduce exciting targeted therapies.
Blood Cancer Journal · 2022 · 1 citations · open access
Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy
AbstractCombined modality therapy (CMT) consisting of chemotherapy followed by radiation therapy (RT) is an accepted standard of care for stage I-II Hodgkin lymphoma (HL). The German Hodgkin Study Group trials HD7-HD11 [ 1 ] helped to establish the parameters for CMT, ultimately leading to HD10 and HD11 and adoption of 20 Gy and 30 Gy, using involved field RT (IFRT), as the standard dose of RT following ABVD for favorable and unfavorable HL, respectively. Relapse has not to be eliminated, however. For example, the HD10 trial reported a 10 year progression-free survival rate of 87% [ 1 ].
Pediatric Hematology/Oncology and Immunopathology · 2018 · 1 citations
Hodgkin's lymphoma relapses and refractory forms therapy variants in children, adolescents and young adults
AbstractHodgkin lymphoma has been studied more than any other type of lymphoma. The result of those studies has lead to rapid advances in the diagnosis and treatment of the disease. The vast majority of Hodgkin lymphoma patients can be cured after first line treatment. And even for those patients who relapse or become refractory, secondary therapies are often successful in providing another remission and cure the patient. The prescribed type of treatment for individual patients depends on several factors, such as time of relapse occurance, the patient’s age, overall health and previous therapies received.
Annals of Advanced Biomedical Sciences · 2021 · 1 citations · open access
Hodgkin Lymphoma in Nigeria: Prevalence, Mechanisms of Tumorigenesis and Diagnosis
AbstractHodgkin lymphoma (HL) is an uncommon neoplasm where tumor stems from a certain kind of leukocytes known as B-cell. This lymphoid malignancy involves outlying lymph gland which may extend to tissues. Research estimates 40% of patients are diagnosed from constitutive signs while early detection is a challenge. The Hodgkin Reed-Stenberg cells is established as the hallmark of Hodgkin lymphoma but multiple underlying mechanisms are involved. Hodgkin lymphoma spreads across different regions with limitations of effective control, hence there is a need to fully understand its tumorigenesis and diagnosis. We reviewed the multiphase deregulated signalling pathways and several interactions amongst cells, these characteristics can proffer new breakthrough to target therapeutics either through direct inhibition of affected signalling pathways or Hodgkin Reed-Stenberg cells associated with diverse cellular infiltrates within the lymph cell. HL incidence in Nigeria is similar to the incidence in other regions but there is a higher death rate in Nigeria. Nigeria bears the second highest burden of HIV globally which contributes to incidence of HL. Also, Epstein-Barr virus increases the risk of the disease, which is also prevalent in Nigeria. Lymphomas are associated with higher cancer-related deaths especially in HIV-infected persons with 2.5times lower 2-year survival chance compared to HIV-uninfected persons and late stage of lymphoma was also a contributing factor to the survival outcomes. Hence, to reduce the burden of the disease, an understanding of the aetiology, epidemiology, and biochemical mechanisms of the lymphoma is needed which are herein reviewed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
